Connecting you to content on EBSCOhost

Works by Widmer, Albert

Results: 4

1

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.

Published in:

Rheumatology & Therapy, 2019, v. 6, n. 3, p. 393, doi. 10.1007/s40744-019-0163-5

By:

Kivitz, Alan J.;
Nash, Peter;
Tahir, Hasan;
Everding, Andrea;
Mann, Heřman;
Kaszuba, Andrzej;
Pellet, Pascale;
Widmer, Albert;
Pricop, Luminita;
Abrams, Ken

Publication type:

Article

2

Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.

Published in:

2011

By:

Alten, Rieke;
Gomez-Reino, Juan;
Durez, Patrick;
Beaulieu, Andre;
Sebba, Anthony;
Krammer, Gerhard;
Preiss, Ralph;
Arulmani, Udayasankar;
Widmer, Albert;
Gitton, Xavier;
Kellner, Herbert

Publication type:

journal article

3

Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.

Published in:

2016

By:

Tlustochowicz, Witold;
Rahman, Proton;
Seriolo, Bruno;
Krammer, Gerhard;
Porter, Brian;
Widmer, Albert;
Richards, Hanno B.

Publication type:

journal article

4

257 Secukinumab demonstrates a consistent safety profile with up to 5 years' treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses.

Published in:

2019

By:

McInnes, Iain B;
Mease, Philip J;
Reich, Kristian;
Nash, Peter;
Widmer, Albert;
Abrams, Ken;
Pricop, Luminita;
Fox, Todd

Publication type:

Abstract